Project Grant R01DE036166
- The National Institute of Dental and Craniofacial Research awarded the University of Illinois $576,957 on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop and evaluate nanotherapeutic and immunotherapeutic approaches for periodontal disease targeting inflammatory and osteoclastogenic pathways. The project develops site-specific nanoparticle platforms designed to attenuate disease progression and preserve alveolar bone. Aim 1 evaluates myeloid...
- The National Institute of Dental and Craniofacial Research awarded the Board of Regents of the University of Nebraska $383,750 on August 26, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop multimodal bioelectroceutical strategies for alveolar bone regeneration in diabetic and aged patients. The University of Nebraska Medical Center in Omaha, Nebraska is developing an integrated approach combining electrical stimulation, small-molecule pharmacologic agents,...
- The National Institute of Dental and Craniofacial Research awarded the University of Pittsburgh $679,631 on February 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate treatment for peri-implantitis via local immunomodulation and the microbiome. The project develops microparticle-based drug delivery systems that provide local, sustained delivery of cytokines and chemokines to modulate the host immune response in peri-implantitis, an inflammatory...
- The National Institute of Dental and Craniofacial Research awarded The Ohio State University $469,207 on February 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct pharmacological inhibition of ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) to promote cementum regeneration and restore periodontal attachment and function. The research addresses periodontal disease and cementum defects, particularly in hypophosphatasia (HPP), a mineralization...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Illinois $249,000 on August 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop bone-like organoids that elucidate how immune responses influence craniofacial bone healing and regeneration. The recipient will establish bone-like organoids as predictive tools for craniofacial bone repair...
- The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health within the Department of Health and Human Services, awarded $435,875 to Indiana University Indianapolis on July 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate oxylipin-mediated biofilm colonization in peri-implant disease. The research explores the role of oxylipins in regulating bacterial biofilm formation around dental implants. The study aims...
- The National Institute of Dental and Craniofacial Research awarded Loma Linda University $358,823 on September 11, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct structural-functional studies of gingipain biogenesis and localization in periodontitis research. The research addresses therapeutic gaps in managing periodontitis, a chronic disease linked to systemic diseases including atherosclerosis, rheumatoid arthritis, cancers, diabetes, and Alzheimer's...
- The National Institute of Dental and Craniofacial Research awarded the University of Illinois $320,660 on April 6, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the immunoregulatory role of dendritic cell subsets in periodontal disease. The award funds research examining how three major dendritic cell subsets—myeloid, lymphoid, and plasmacytoid dendritic cells—respond during periodontal disease resolution and interact functionally with periopathic...
- The National Institute of Dental and Craniofacial Research awarded Virginia Commonwealth University $310,500 on June 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the role of nuclear bone morphogenetic protein 2 (NBMP2) in macrophage-mediated periodontal regeneration and bone repair. The research will characterize the regulation of macrophage NBMP2 and BMP2 expression, functionally dissect NBMP2-regulated STAT6 signaling pathways in macrophages,...
- Federal Grant Award Summary Award Details: The National Institute of Dental and Craniofacial Research (NIDCR) awarded Augusta University Research Institute, Inc. a Project Grant totaling $645,009 under the Oral Diseases and Disorders Research program (CFDA 93.121). The award period runs from June 15, 2025, through June 14, 2027. Research Scope: This grant funds a research project investigating the molecular mechanisms of alveolar bone loss in periodontitis through examination of...
The National Institute of Dental and Craniofacial Research awarded The University of Iowa $540,583 on August 6, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop an innovative mitochondria-targeted strategy for alveolar bone regeneration in periodontitis. The research, led by PI Sun's group, advances a patent-pending alpha-ketoglutarate-based polymer (PAKG) derived from a key metabolite in the tricarboxylic acid cycle. PAKG nanoparticles are designed to be internalized by osteogenic cells, restore cellular energy production, reduce inflammation-induced reactive oxygen species, and promote robust alveolar bone regeneration. Pilot studies demonstrate that PAKG nanoparticles significantly enhance osteoblastic differentiation in vitro and promote large cranial bone regeneration in vivo. A single local gingival injection of PAKG nanoparticles reduces alveolar bone loss in a ligature-induced periodontitis mouse model. The research addresses a critical clinical gap: current treatments, including scaling, root planing, and antibiotics, do not effectively block periodontal bone loss or regenerate damaged structures, and regenerative methods such as grafts and growth factors show inconsistent success, particularly in irregular or horizontal defects. Work is performed at Iowa City, Iowa. The period of performance extends from August 6, 2026, to April 30, 2031. This is a Project Grant, the standard assistance type for NIH research project awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $540.6k | 8/7/26 |